關于非小細胞肺癌（<\/b>NSCLC）<\/b><\/p> \n
肺癌是全球致死率最高的一類惡性腫瘤，[6]<\/sup>預計到2040年全球發病數將突破300萬例。[7]<\/sup>其中，非小細胞肺癌（NSCLC）是最常見的病理類型。[8]<\/sup>該疾病確診時通常已屆晚期，[9]<\/sup>患者5年生存率不足30%。[10]<\/sup>晚期非小細胞肺癌（NSCLC）患者往往承受著身體機能衰退、心理創傷和情緒困擾等多重打擊，生活質量因而大打折扣。現階段，晚期非小細胞肺癌（NSCLC）患者仍存在巨大的未滿足需求。值得注意的是，多達4%的肺癌病例由HER2基因突變（或變異）驅動。[11]<\/sup>HER2基因突變會導致過度表達與過度激活，進而引發細胞增殖失控、抑制細胞死亡，最終誘導腫瘤生長、癌細胞擴散。<\/p> \n 關于勃林格殷格翰在腫瘤學領域 <\/b><\/p> \n 勃林格殷格翰致力于推動具有深遠意義的科學進步，為癌癥患者生活帶來變革，最終實現治愈各類癌癥。公司世世代代推動科學創新的承諾，在穩健的癌細胞靶向與免疫腫瘤學在研療法產品線，以及巧妙的聯合療法策略中得到生動體現。在腫瘤學領域，勃林格殷格翰矢志不渝地構建廣泛合作研究網絡，積極尋求多元化的創新思路，這對于攻克極具挑戰且影響巨大的癌癥研究領域至關重要。簡而言之，對于勃林格殷格翰，攻克癌癥關乎當前和未來的世世代代。<\/p> \n 關于勃林格殷格翰與中國生物制藥的戰略合作<\/b><\/p> \n 勃林格殷格翰與中國生物制藥建立戰略合作伙伴關系，致力于為中國大陸市場帶來創新的腫瘤療法。此次合作將憑借雙方的互補優勢，為中國的癌癥患者提供更多更好的治療方案。雙方將合作勃林格殷格翰多個處于臨床開發晚期階段的創新腫瘤產品。宗艾替尼是勃林格殷格翰和中國生物制藥在中國大陸的戰略合作產品之一。<\/p> \n [1] HERNEXEOS Prescribing Information <\/p>"];
$("#dvExtra").html(content_array[0]);})(); \n \n
\n
[2] Heymach, J. et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med. 2025;01-13.
[3] Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906.
[4] Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51
[5] Zeng J, Ma W, Young RB, Li T. Targeting HER2 genomic alterations in non-small cell lung cancer. J Natl Cancer Cent. 2021 May 3;1(2):58-73.
[6] World Health Organization Cancer Factsheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (Accessed April 2025).
[7] International Agency for Research on Cancer – World Health Organization. Rates of trachea, bronchus and lung cancer. Available at: https:\/\/gco.iarc.fr\/tomorrow\/en (Accessed August 2024).
[8] Zappa C & Mousa Non-small cell lung cancer: current treatment and future advances, Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300.
[9] Polanco D et al. Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study. J Thorac Dis 2021;13:1485–1494
[10] National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html (Accessed: August 2024).
[11] Arcila, M. E. et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 18, 4910–4918 (2012).<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n